Go Deep
Perseus Proteomics Inc.
Perseus Proteomics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,362 | -2.8 | 2.06 | 0.00 | 82.93 |
Perseus Proteomics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 35,184,000.0 | 32,404,000.0 | 42,140,000.0 | 37,491,000.0 |
| Net Profit | -202,603,000.0 | -170,327,000.0 | -168,386,000.0 | -203,322,000.0 |
| EPS | -11.8 | — | — | — |
Perseus Proteomics Inc. Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 135,507,000.0 | 120,375,000.0 | 100,402,000.0 | 94,201,000.0 | — |
| Net Profit | -718,108,000.0 | -904,800,000.0 | -1,104,460,000.0 | -786,999,000.0 | — |
| EPS | -48.2 | -63.4 | -93.7 | -66.9 | — |
Perseus Proteomics Inc. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 1,623,541,000.0 | 1,818,837,000.0 | 1,693,810,000.0 | 2,566,650,000.0 | — |
| Total Liabilities | 405,771,000.0 | 386,430,000.0 | 295,465,000.0 | 170,105,000.0 | — |
| Total Equity | 1,217,770,000.0 | 1,432,407,000.0 | 1,398,345,000.0 | 2,396,545,000.0 | — |
Owes vs Owns
Perseus Proteomics Inc. owed ¥0.27 for every ¥1 it owned in Jun 2026, up from ¥0.07 in Mar 2023.
| Period | Jun 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.27× | 0.25× | 0.21× | 0.17× | 0.07× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Perseus Proteomics Inc. Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 93.3%Receivables 1.1%Other assets 5.1%
How it's funded — Mar 2026
Payables 1.7%Other liabilities 23.3%Shareholders' equity 75.0%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1,515.3 | 1,667.9 | 1,541.4 | 2,444.9 |
| Receivables | 18.1 | 22.2 | 13.7 | 9.8 |
| Inventory | 7.1 | 5.3 | 4.4 | 3.2 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 83.0 | 123.4 | 134.3 | 108.7 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 27.8 | 79.3 | 66.5 | 66.7 |
| Other liabilities | 377.9 | 307.1 | 228.9 | 103.4 |
| Shareholders' equity | 1,217.8 | 1,432.4 | 1,398.3 | 2,396.5 |
| Net tangible assets | 1,217.8 | 1,432.4 | 1,398.3 | 2,396.5 |
Perseus Proteomics Inc. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -653,334,000.0 | -719,485,000.0 | -833,898,000.0 | -564,274,000.0 | — |
| Investing Activities | -10,062,000.0 | -75,157,000.0 | -150,343,000.0 | -212,989,000.0 | — |
| Financing Activities | 497,333,000.0 | 923,381,000.0 | 63,943,000.0 | -20,000.0 | — |